Advertisement
U.S. markets closed

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
2.2300+0.2500 (+12.63%)
At close: 03:59PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9800
Open2.0000
Bid2.2100 x 0
Ask2.2300 x 0
Day's Range2.0000 - 2.2400
52 Week Range1.2200 - 5.8400
Volume55,925
Avg. Volume43,772
Market Cap102.535M
Beta (5Y Monthly)1.73
PE Ratio (TTM)N/A
EPS (TTM)-1.2400
Earnings DateApr 10, 2024 - Apr 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.46
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for TH.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform

      Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger the cGAS/STING pathway potentiate and anti-PD-L1 immunotherapy tumor cell killing MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative

    • GlobeNewswire

      Theratechnologies Announces Update on its Preclinical Oncology Research Program

      Company continues to shift to commercial focus as it seeks partners to advance R&D MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities. The Company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendus

    • GlobeNewswire

      Theratechnologies Appoints Jordan Zwick to its Board of Directors

      MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company’s Audit Committee. “We welcome Jordan Zwick to the Board as an important addition to our esteemed group of